EarningsQ4 2026 Earnings Report

Fisher & Paykel Healthcare Corporation Limited (FPLB) Q4 2026 Earnings Report

1 Followers

Previous Report: Q2 2026

DE:FPLB Q4 2026 EPS Results

Actual EPS€0.22

Consensus EPS€0.21

Beat/MissBeat by +<€0.01

One Year Ago EPS€0.19

DE:FPLB Q4 2026 Revenue Results

Actual Revenue€619.89M

Expected Revenue€606.95M

Beat/MissBeat by +€12.94M

YoY Revenue Growth+14.74%

Earnings Announcement Details

QuarterQ4 2026

Date05/25/2026

TimeAfter Close

Conference CallMonday, May 25, 2026

DE:FPLB Upcoming Earnings

Fisher & Paykel Healthcare Corporation Limited's next earnings date is estimated for November 25, 2026, based on past reporting schedules.

Q4 2026 Earnings Call Audio

DE:FPLB Q4 2026 Earnings Call

0:00 / 0:00

Q4 2026 Earnings Slide Deck

Q4 2026 Earnings Call Summary

Q4 2026

Earnings Call Date:May 25, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call conveyed a predominantly positive operational and financial performance: strong top-line growth, substantial NPAT expansion, margin improvement, robust cash flow, higher dividends and continued investment in capacity and R&D. The company provided constructive FY'27 guidance but also clearly articulated material near-term headwinds — notably U.S. tariffs, surcharges from the Middle East conflict, FX/hedging losses, and the risk of hardware growth normalizing after an exceptional year. Management stressed that continuous improvement and manufacturing/network flexibility should offset many of these pressures, but several macro and policy risks remain.

Company Guidance

Management guided FY27 operating revenue of NZ$2.45–2.57 billion (implying ~6–11% growth, midpoint ≈9%) and net profit after tax of about NZ$500–550 million, built on assumptions including a 10% U.S. tariff on certain New‑Zealand‑made respiratory products for the full year (estimated ~70 basis‑point adverse gross‑margin impact, ~20 bps improvement versus FY26), continued Middle East‑related surcharges of ~45 bps (raw materials) and ~25 bps (freight) (netting to ~50 bps negative to gross margin year‑on‑year after tariff movement) that management expects to more than be offset by continuous‑improvement savings; FY27 capital expenditure is expected at ~NZ$230 million (including ~NZ$125m on land and buildings), operating expenses (R&D and SG&A) are guided to mid‑ to high‑single‑digit growth (R&D was NZ$235.5m, 10% of revenue in FY26), and management highlighted FX and air‑freight as risks (FY26 hedging losses ~$21m pretax; end‑April FY27 hedging loss estimate ~$17m and ~$1m translation loss; ~NZ$2–3m NPAT sensitivity per 1% currency move).

Strong Revenue Growth

Operating revenue of $2.3 billion, up 14% on prior year (12% in constant currency). FY'27 guidance: $2.45–$2.57 billion (approx. 6%–11% growth).

Material Net Profit Growth

Net profit after tax $468.5 million, up 24% on prior year (28% in constant currency). FY'27 NPAT guidance: $500–$550 million.

Hospital Segment Outperformance

Hospital operating revenue $1.5 billion, up 18% (15% constant currency). Hospital hardware revenue up ~27% in constant currency; new applications consumables up 18% (16% CC); Hospital consumables overall up 14% CC.

Homecare Growth and Product Momentum

Homecare revenue $802.7 million, up 8% (7% CC). OSA mask revenue up 7% (5% CC) driven by new Solo and Nova nasal/pillows ranges; Homecare hardware also showed growth.

Margin Expansion

Gross margin 63.7%, an increase of 122 basis points in constant currency versus prior year. Operating margin 27.6%, up 277 basis points in constant currency.

Strong Cash Generation

Operating cash flow $663 million, up 21% year-on-year. Net cash $401 million at 31 March 2026 and gearing of -22.8%.

Capital Investment for Capacity

Capital expenditure (including intangibles) $195 million (up from $103 million), including $132 million on a new building (East Tamaki) and payment on Karaka land; FY'27 capex guidance ~ $230 million.

Shareholder Returns Increased

Total dividends declared $0.52 per share, up 22% on prior year; final dividend $0.33 per share (65% payout of full year profit).

DE:FPLB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 25, 2026	2027 (Q2)	0.24 / -	0.18	―
May 25, 2026	2026 (Q4)	0.21 / 0.22	0.19	13.16% (+0.03)
Nov 25, 2025	2026 (Q2)	0.17 / 0.18	0.13	38.46% (+0.05)
May 27, 2025	2025 (Q4)	0.18 / 0.19	0.135	41.26% (+0.06)
Nov 27, 2024	2025 (Q2)	0.13 / 0.13	0.098	33.33% (+0.03)
May 27, 2024	2024 (Q4)	0.13 / 0.13	0.135	0.00% (0.00)
Nov 28, 2023	2024 (Q2)	0.10 / 0.10	0.083	18.18% (+0.02)
May 25, 2023	2023 (Q4)	0.13 / 0.13	0.135	0.00% (0.00)
Nov 28, 2022	2023 (Q2)	0.14 / 0.08	0.192	-56.92% (-0.11)
May 25, 2022	2022 (Q4)	- / 0.13	0.257	-47.67% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed